Safety Study of Galantamine in Tic Disorders

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine the safety, tolerability and efficacy of galantamine in tic disorders. The impact of galantamine on commonly associated behaviors (i.e. attention, obsessions, etc.) will also be examined.

Clinical Trial Description

Modulation of cholinergic activity is a growing focus in neurologic therapeutics especially for dementing disorders such as Alzheimer disease. Treatment with the recently developed cholinesterase inhibitor, galantamine, has demonstrated significant improvement with few issues related to tolerability. In addition to inhibiting the activity of acetylcholinesterase, galantamine also modulates the activity of nicotinic cholinergic receptors by an allosteric mechanism. As a result, galantamine therapy may be beneficial when the response to other agents has been limited.

Cholinesterase inhibitor therapy has been reported to improve motor tics in children with TS refractory to more traditional therapies. Symptoms of co-morbid behavioral disorders, primarily inattention, were also improved. Cholinergic modulation appears a promising avenue for managing tic disorders.

Men and women (18 - 50 years of age) fulfilling DSM IV criteria for the diagnosis of chronic motor tic disorder, chronic vocal tic disorder or Tourette Syndrome and experiencing suboptimal control of tics on current therapy will be enrolled into this open label evaluation of galantamine. A total of 6 visits will be required over 22 weeks. Participants will follow a standard 4 week titration schedule achieving 12 mg bid after 8 weeks. They will maintain at 12 mg bid, or the maximum tolerated dose, for a further 8 weeks and then be withdrawn from therapy. The difference in tic severity prior to and upon completion of therapy will be examined. The impact of treatment upon obsessions/compulsions, attention/concentration, depression, anxiety and quality of life will also be determined. ;

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT00226824
Study type	Interventional
Source	Parkinson's Disease and Movement Disorders Center
Contact
Status	Terminated
Phase	Phase 4
Start date	September 2005
Completion date	May 2007

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT00965211` - Evaluation of the HBDL Coil Transcranial Magnetic Stimulation (TMS) Device - Safety and Feasibility Study for the Treatment of Tourette Syndrome	N/A
Recruiting	`NCT00152750` - Study of Clonidine on Sleep Architecture in Children With Tourette's Syndrome (TS) and Comorbid ADHD	Phase 4
Completed	`NCT00241176` - Open Label Trial of Aripiprazole in Children and Adolescents With Tourette's Disorder	Phase 4
Completed	`NCT01244633` - Ecopipam Treatment of Tourette Syndrome	Phase 1/Phase 2
Recruiting	`NCT04805385` - Effects of Lactobacillus Plantarum PS128 in Patients With Tourette's Syndrome	N/A
Completed	`NCT00026000` - Brain Activation in Vocal and Motor Tics	N/A
Terminated	`NCT00001260` - Brain Tissue Collection for Neuropathological Studies
Completed	`NCT02102698` - Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years	Phase 2
Withdrawn	`NCT02112253` - Optimising Anterior Pallidal Deep Brain Stimulation for Tourette's Syndrome	Phase 1/Phase 2
Withdrawn	`NCT01133353` - A Study of the Effectiveness and Safety of Tetrabenazine MR in Pediatric Subjects With Tourette's Syndrome	Phase 2
Completed	`NCT02205918` - Brain-Behavior Interactions in Tic Suppression
Terminated	`NCT00282139` - Aripiprazole in the Treatment of Tourette's Syndrome	N/A
Completed	`NCT03042507` - Psychosocial Intervention for Young Children With Chronic Tics	N/A
Completed	`NCT01019343` - Physiological Investigations of Movement Disorders	N/A
Completed	`NCT02619084` - Subthalamic Stimulation in Tourette's Syndrome	Phase 2
Completed	`NCT00368433` - Hypersensitivity in Tourette Syndrome	N/A
Withdrawn	`NCT01475383` - Study Evaluating The Safety And Efficacy Of PF-03654746 In Adult Subjects With Tourette's Syndrome	Phase 2
Not yet recruiting	`NCT06361004` - Exploring DBS Efficacy in Treatment-refractory Tourette's Syndrome	N/A
Completed	`NCT00139308` - High Frequency Stimulation of the GPi or Thalamus in Tourette's Syndrome	Phase 1

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.